{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T23:55:55Z","timestamp":1782777355433,"version":"3.54.5"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2024,7,20]],"date-time":"2024-07-20T00:00:00Z","timestamp":1721433600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,7,20]],"date-time":"2024-07-20T00:00:00Z","timestamp":1721433600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100015272","name":"Societ\u00e0 Italiana di Farmacologia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100015272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1007\/s40261-024-01381-z","type":"journal-article","created":{"date-parts":[[2024,7,20]],"date-time":"2024-07-20T11:01:32Z","timestamp":1721473292000},"page":"577-586","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["The Early Access and the Potential Cost Savings by the Compassionate Use of Onco-haematological Drugs: Results from the Italian Study Compass-O"],"prefix":"10.1007","volume":"44","author":[{"given":"Irene","family":"Dell\u2019Anno","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo","family":"Dondi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Immacolata","family":"Esposito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annamaria","family":"Mascolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annalisa","family":"Capuano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"de Marchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriano","family":"Cristinziano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenico","family":"Tarantino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcello","family":"Pani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Masini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Donati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Rossin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Serafini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Bagaglini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriella","family":"Bonanni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tommaso","family":"Gregori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arturo","family":"Cavaliere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Matocci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"D\u2019Arpino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nello","family":"Martini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8648-8961","authenticated-orcid":false,"given":"Carlo","family":"Piccinni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,20]]},"reference":[{"key":"1381_CR1","unstructured":"European Medicines Agency. Compassionate use. Available from: https:\/\/ema.europa.eu\/en\/human-regulatory-overview\/research-development\/compassionate-use. Accessed 9 Apr 2024."},{"issue":"2","key":"1381_CR2","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1177\/2168479017694848","volume":"51","author":"T Watson","year":"2017","unstructured":"Watson T. A global perspective on compassionate use and expanded access. Ther Innov Regul Sci. 2017;51(2):143\u20135.","journal-title":"Ther Innov Regul Sci."},{"issue":"1","key":"1381_CR3","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1186\/s12913-021-07255-w","volume":"21","author":"C Jommi","year":"2021","unstructured":"Jommi C, Pantellini F, Stagi L, Verykiou M, Cavazza M. The economic impact of compassionate use of medicines. BMC Health Serv Res. 2021;21(1):1303.","journal-title":"BMC Health Serv Res"},{"issue":"1","key":"1381_CR4","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1186\/s12916-017-0910-9","volume":"15","author":"J Borysowski","year":"2017","unstructured":"Borysowski J, Ehni HJ, G\u00f3rski A. Ethics review in compassionate use. BMC Med. 2017;15(1):136.","journal-title":"BMC Med"},{"issue":"1","key":"1381_CR5","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s12910-018-0263-8","volume":"19","author":"L De Panfilis","year":"2018","unstructured":"De Panfilis L, Satolli R, Costantini M. Compassionate use programs in Italy: ethical guidelines. BMC Med Ethics. 2018;19(1):22.","journal-title":"BMC Med Ethics"},{"issue":"4","key":"1381_CR6","doi-asserted-by":"publisher","first-page":"244","DOI":"10.5582\/irdr.2016.01054","volume":"5","author":"G Balasubramanian","year":"2016","unstructured":"Balasubramanian G, Morampudi S, Chhabra P, Gowda A, Zomorodi B. An overview of compassionate use programs in the European Union member states. Intractable Rare Dis Res. 2016;5(4):244\u201354.","journal-title":"Intractable Rare Dis Res."},{"key":"1381_CR7","unstructured":"Ministero della Salute. Decreto Ministeriale del 7 settembre 2017. Disciplina dell\u2019uso terapeutico di medicinale sottoposto a sperimentazione clinica. GU Serie Generale n.256 del 02-11-20172017."},{"issue":"20","key":"1381_CR8","first-page":"6365","volume":"25","author":"D Pilunni","year":"2021","unstructured":"Pilunni D, Daloisio V, Campopiano R, Pani M, Navarra P. Compassionate drug uses and saving for the national health system: the case study of Fondazione Policlinico Gemelli. Eur Rev Med Pharmacol Sci. 2021;25(20):6365\u201377.","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"1381_CR9","first-page":"109","volume":"7","author":"P Raimondo","year":"2020","unstructured":"Raimondo P, Casilli G, Isernia M, Lidonnici D, Ravasio R, Ronco V, et al. Le tempistiche autorizzative di AIFA: un confronto tra le due commissioni consultive e tecnico-scientifiche succedutesi nel periodo 2015\u20132020. Glob Reg Health Technol Assess. 2020;7:109\u201314.","journal-title":"Glob Reg Health Technol Assess."},{"key":"1381_CR10","unstructured":"Agenzia Italiana del Farmaco (AIFA). Rapporto sulle tempistiche di autorizzazione delle procedure di prezzi e rimborso dei farmaci nel triennio 2018-2020: risultati preliminari area strategia ed economia del farmaco settore HTA ed economia del farmaco: Settembre 2021. 2021. Available from: https:\/\/www.aifa.gov.it\/documents\/20142\/1307543\/2021.09.06_Rapporto_procedure_prezzi_rimborso_farmaci_triennio_2018-2020.PDF. Accessed 9 Apr 2024."},{"issue":"1","key":"1381_CR11","first-page":"43","volume":"59","author":"D Pilunni","year":"2023","unstructured":"Pilunni D, Navarra P. Compassionate drug uses in Italy: analysis of regional and local diffusion. Ann Ist Super Sanita. 2023;59(1):43\u201350.","journal-title":"Ann Ist Super Sanita"},{"key":"1381_CR12","doi-asserted-by":"publisher","unstructured":"Wu J, Yang Y, Yu J, Qiao L, Zuo WA-O, Zhang B. Efficacy and safety of compassionate use for rare diseases: a scoping review from 1991 to 2022. Orphanet J Rare Dis. 2023;18(1):368. https:\/\/doi.org\/10.1186\/s13023-023-02978-x.","DOI":"10.1186\/s13023-023-02978-x"},{"key":"1381_CR13","doi-asserted-by":"publisher","unstructured":"Jommi CA-O, Pantellini F, Giuliani GA-OX, Cavazza MA-O. Impatto economico di 14 programmi di uso compassionevole dei farmaci in Italia, nella prospettiva del Servizio Sanitario Nazionale. Glob Reg Health Technol Assess. 2024;11:115\u201323. Italian. https:\/\/doi.org\/10.33393\/grhta.2024.2735.","DOI":"10.33393\/grhta.2024.2735"},{"key":"1381_CR14","unstructured":"Gatti L. L\u2019Italia prova a inserire i Pdta digitali per governare l\u2019innovazione. 2024. Available from: https:\/\/www.aboutpharma.com\/digital-health\/litalia-prova-a-inserire-i-pdta-digitali-per-governare-linnovazione\/. Accessed 10 Apr 2024."},{"issue":"10","key":"1381_CR15","doi-asserted-by":"publisher","first-page":"e801","DOI":"10.1016\/S2352-3026(23)00243-0","volume":"10","author":"MA Dimopoulos","year":"2023","unstructured":"Dimopoulos MA, Hungria VTM, Radinoff A, Delimpasi S, Mikala G, Masszi T, et al. Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, randomised study. Lancet Haematol. 2023;10(10):e801\u201312.","journal-title":"Lancet Haematol."},{"key":"1381_CR16","unstructured":"European Medicines Agency. EMA confirms recommendation for non-renewal of authorisation of multiple myeloma medicine Blenrep. 15 December 2023. Available from: https:\/\/www.ema.europa.eu\/en\/news\/ema-confirms-recommendation-non-renewal-authorisation-multiple-myeloma-medicine-blenrep. Accessed 9 Apr 2024."},{"key":"1381_CR17","unstructured":"Agenzia Italiana del Farmaco (AIFA). Innovative medicinal products. Available from: https:\/\/www.aifa.gov.it\/en\/farmaci-innovativi. Accessed 9 Apr 2024."},{"key":"1381_CR18","unstructured":"The Medicines Utilisation Monitoring Centre. National report on medicines use in Italy. 2022. Rome: Italian Medicines Agency; 2023."},{"key":"1381_CR19","unstructured":"Agenzia Italiana del Farmaco (AIFA). Determina 26 giugno 2023. Riclassificazione del medicinale per uso umano \u00abEnhertu\u00bb, ai sensi dell\u2019articolo 8, comma 10, della legge 24 dicembre 1993, n. 537. (Determina n. 452\/2023). GU Serie Generale n.153 del 03-07-2023; 2023."},{"key":"1381_CR20","unstructured":"Agenzia Italiana del Farmaco (AIFA). Determina 15 dicembre 2023 Regime di rimborsabilita' e prezzo a seguito di nuove indicazioni terapeutiche del medicinale per uso umano \u00abEnhertu\u00bb. (Determina n. 760\/2023). GU Serie Generale n.296 del 20-12-2023; 2023."},{"issue":"12","key":"1381_CR21","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1056\/NEJMoa2115022","volume":"386","author":"J Cort\u00e9s","year":"2022","unstructured":"Cort\u00e9s J, Kim SB, Chung WP, Im SA, Park YH, Hegg R, et al. Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer. N Engl J Med. 2022;386(12):1143\u201354.","journal-title":"N Engl J Med"},{"issue":"1","key":"1381_CR22","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2203690","volume":"387","author":"S Modi","year":"2022","unstructured":"Modi S, Jacot W, Yamashita T, Sohn J, Vidal M, Tokunaga E, et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N Engl J Med. 2022;387(1):9\u201320.","journal-title":"N Engl J Med"},{"key":"1381_CR23","unstructured":"Agenzia Italiana del Farmaco (AIFA). Determina 24 novembre 2021 Riclassificazione del medicinale per uso umano \u00abBlenrep\u00bb, ai sensi dell'articolo 8, comma 10, della legge 24 dicembre 1993, n. 537. (Determina n. DG\/1388\/2021). GU Serie Generale n.291 del 07-12-20212021."},{"key":"1381_CR24","unstructured":"Agenzia Italiana del Farmaco (AIFA). Farmaci a uso compassionevole (compassione use programs). 7 June 2024. Available from: https:\/\/www.aifa.gov.it\/en\/farmaci-a-uso-compassionevole. Accessed 26 Jun 2024."},{"key":"1381_CR25","doi-asserted-by":"publisher","unstructured":"Montanaro NA-O, Melis M, Proni S, Chiabrando G, Motola D. Six-year activity on approval of compassionate use of medicines by the Ethics Committee of the University Hospital of Bologna (Italy): time to update rules and recommendations. Eur J Clin Pharmacol. 2017;73(4):479\u201385. https:\/\/doi.org\/10.1007\/s00228-016-2186-y. Epub 2016 Dec 29.","DOI":"10.1007\/s00228-016-2186-y"},{"key":"1381_CR26","unstructured":"Agenzia Italiana del Farmaco (AIFA). Legge 23 dicembre 1996, n. 648 Conversione in legge del decreto-legge 21 ottobre 1996, n. 536, recante misure per il contenimento della spesa farmaceutica e la rideterminazione del tetto di spesa per l\u2019anno 1996. GU Serie Generale n.300 del 23-12-1996; 1996."},{"key":"1381_CR27","unstructured":"Agenzia Italiana del Farmaco (AIFA). LEGGE 24 novembre 2003, n. 326. Conversione in legge, con modificazioni, del decreto-legge 30 settembre 2003, n. 269, recante disposizioni urgenti per favorire lo sviluppo e per la correzione dell'andamento dei conti pubblici. 2003. https:\/\/www.normattiva.it\/uri-res\/N2Ls?urn:nir:stato:legge:2003-11-24;326!vig=. Accessed 12 Jul 2024."},{"key":"1381_CR28","doi-asserted-by":"publisher","unstructured":"Popoli PA-O, Giuliani GA-OX, Cavaliere AA-OX, Jommi CA-O. Accesso precoce ai farmaci: una proposta di riforma per il Servizio Sanitario Nazionale. Glob Reg Health Technol Assess. 2024;11:148\u201353. Italian. https:\/\/doi.org\/10.33393\/grhta.2024.3098.","DOI":"10.33393\/grhta.2024.3098"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-024-01381-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-024-01381-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-024-01381-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T10:26:01Z","timestamp":1724408761000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-024-01381-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,20]]},"references-count":28,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["1381"],"URL":"https:\/\/doi.org\/10.1007\/s40261-024-01381-z","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,20]]},"assertion":[{"value":"2 July 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was funded by the Italian Society of Pharmacology (Societ\u00e0 Italiana Farmacologia).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The authors have no conflicts of interest that are directly relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"The study was approved by the Ethics Committee of the coordinating centre L. Vanvitelli University of Campania, Naples, Italy (Protocol No. 0037627 of 14 December, 2022).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The data that support the findings of this study are not openly available to maintain the privacy of study participants. For more information, please contact the corresponding author. All other data relevant to the study were obtained from the published literature or other publicly available sources and have been presented in the article and the supplementaryiInformation.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"ID, CP: conceptualisation, methodology, validation, formal analysis, investigation, resources, data curation, writing - original draft, writing - review and editing, visualisation; LD: methodology, software, validation, formal analysis; IE, NM, AC, MP, AC, AD: conceptualisation, supervision, project administration, funding acquisition; AM: writing - original draft, writing - review and editing; AC: conceptualisation, supervision, funding acquisition; GdM, AC, DT, CM, CD, ER, AS, GB, GB, TG, RM: resources, writing - review and editing. All authors read and approved the final manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}